tiprankstipranks
Medexus Awaits FDA Decision on Treosulfan
Company Announcements

Medexus Awaits FDA Decision on Treosulfan

Medexus Pharmaceuticals Inc (TSE:MDP) has released an update.

Don't Miss Our Christmas Offers:

Medexus Pharmaceuticals announces that the FDA has accepted for review the resubmission of their New Drug Application for treosulfan, expecting a decision by October 30, 2024. Treosulfan, already successful in Canada, could significantly impact Medexus’s revenue if approved in the US. The company remains optimistic about treosulfan’s approval and its potential in the US market, reflecting its strong performance as a treatment in Europe and Canada.

For further insights into TSE:MDP stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Canadian Auto-Generated NewsdeskMedexus Pharmaceuticals Secures Deal for Trecondyv in Canada
TipRanks Canadian Auto-Generated NewsdeskMedexus Pharmaceuticals Reports Strong Q2 2025 Results
TipRanks Canadian Auto-Generated NewsdeskMedexus Shareholders Show Strong Support at Annual Meeting
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App